HCL
HCL
France, Lyon, France1 results ยท Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Efficacy and Safety of Dalbavancin As Suppressive Therapy | Efficacy and Safety of Dalbavancin; For Acute or Chronic Infections Between July 2019 and December 2024; In Subjects Who Received SAT with DAL | Recruiting | Not stated | 2025-03-28 | NCT06899906 |